TIL Therapy Cleared to Begin Clinical Trial for Patients with Advanced Solid Tumors
TIDAL-01 will be evaluated in patients with advanced or metastatic breast carcinoma, colorectal adenocarcinoma, or uveal melanoma.
Turnstone Biologics’ TIDAL-01 (TBio-4101), an investigational selected
TIDAL-01 consists of autologous tumor-reactive T-cells that have been selected based on potency for expansion with the use of tumor specific antigens. The IND clearance will allow Turnstone Biologics to initiate the planned multicenter, phase 1 STARLING clinical trial (NCT05576077) which will evaluate TIDAL-01 for the treatment of patients with several types of advanced solid tumors with varying mutational burden. This will be the second clinical trial involving TIDAL-01, as Turnstone Biologics’ previously received IND clearance in July of this year for a separate phase 1 clinical trial evaluating TIDAL-01 in patients with cutaneous and non-cutaneous melanoma, which is being carried out in collaboration with Moffitt Cancer Center.2
“Clearance of our IND is a critical milestone for Turnstone in the advancement of our novel TIL therapy pipeline,” Sammy Farah, PhD, president and chief executive officer, Turnstone Biologics, said in a statement regarding the news.1 “TIDAL-01 is a potentially transformative approach to improving the potency of TILs and bringing the clinical benefit of Selected TILs to patients with solid tumor cancers where the unmet medical need is high. We are eager to commence the clinical study for TIDAL-01 and to progress this candidate through the clinic.”
The open-label STARLING trial is expected to enroll approximately 30 patients aged 18 years to 70 years with advanced or metastatic breast carcinoma, colorectal adenocarcinoma, or
Participants will receive non-myeloablative chemotherapy prior to TIL infusion and will be administered IL-2 along with TIDAL-01. After TIDAL-01 infusion and the resolution of IL-2 toxicities patients will receive pembrolizumab every 3 weeks for up to 2 years. The study’s primary end point is the incidence of treatment-emergent adverse events. Secondary end points include the overall response rate for all patients and for each indication, the estimated disease control rate, and the estimated duration of response. The study is expected to begin before the end of the year and has an estimated completion date of June 30, 2024.
“To achieve success against solid tumors, we are applying a differentiated approach with TILs to overcome what we believe to be the greatest barrier to more effective cell therapies: the low amount of T-cells that recognize and attack the tumor,” Stewart Abbot, PhD, chief scientific officer, Turnstone Biologics, added to the statment.1 “In identifying, selecting and expanding these tumor-reactive T-cells, we aim to drive more potent solid tumor killing and improved clinical outcomes in multiple different cancer indications.”
REFERENCES
1. Turnstone Biologics announces FDA clearance of IND for TIDAL-01, a next-generation TIL therapy for solid tumors. News release. Turnstone Biologics Corp. October 31, 2022. https://www.businesswire.com/news/home/20221031005275/en/Turnstone-Biologics-Announces-FDA-Clearance-of-IND-for-TIDAL-01-a-Next-Generation-TIL-Therapy-for-Solid-Tumors
2. Turnstone Biologics and MoffittCancer Center announce strategic alliance to advance next-generation TIL therapies for solid tumors. News release. Turnstone Biologics Corp. July 6, 2022. https://www.businesswire.com/news/home/20220706005321/en/Turnstone-Biologics-and-Moffitt-Cancer-Center-Announce-Strategic-Alliance-to-Advance-Next-Generation-TIL-Therapies-for-Solid-Tumors
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- CGTLive®’s Weekly Rewind – September 12, 2025
September 12th 2025
- Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
September 10th 2025
- CGTLive®’s Weekly Rewind – September 5, 2025
September 5th 2025